Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture
Launched by NOVARTIS PHARMACEUTICALS · Sep 24, 2002
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female ages 50 years or older
- • Must have a recent hip fracture repair in the past 90 days
- • Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture
- Exclusion Criteria:
- • Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate)
- • Other protocol-defined inclusion/exclusion criteria may apply.
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Columbus, Ohio, United States
Columbia, South Carolina, United States
Danville, Virginia, United States
Madison, Wisconsin, United States
Baltimore, Maryland, United States
Birmingham, Alabama, United States
Eureka, California, United States
La Mesa, California, United States
Santa Rosa, California, United States
Lake Worth, Florida, United States
Decatur, Georgia, United States
Gainesville, Georgia, United States
Galesburg, Illinois, United States
Morton Grove, Illinois, United States
Des Moines, Iowa, United States
Portland, Maine, United States
Detroit, Michigan, United States
Woodbury, Minnesota, United States
Rochester, New York, United States
Chapel Hill, North Carolina, United States
Durham, North Carolina, United States
Canfield, Ohio, United States
Philadelphia, Pennsylvania, United States
West Reading, Pennsylvania, United States
Warwick, Rhode Island, United States
Austin, Texas, United States
Houston, Texas, United States
Nuernberg, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials